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Abstract Numerous families exhibiting both frontotem-
poral dementia (FTD) and amyotrophic lateral sclerosis
(ALS) have been described, and although many of these
have been shown to harbour a repeat expansion in
C9ORF72, several C9ORF72-negative FTD-ALS families
remain. We performed neuropathological and genetic
analysis of a large European Australian kindred (Aus-12)
with autosomal dominant inheritance of dementia and/or
ALS. Affected Aus-12 members developed either ALS or
dementia; some of those with dementia also had ALS and/
or extrapyramidal features. Neuropathology was most
consistent with frontotemporal lobar degeneration with
type B TDP pathology, but with additional phosphorylated
tau pathology consistent with corticobasal degeneration.
Aus-12 DNA samples were negative for mutations in all
known dementia and ALS genes, including C9ORF72 and
FUS. Genome-wide linkage analysis provided highly
suggestive evidence (maximum multipoint LOD score of
2.9) of a locus on chromosome 16p12.1–16q12.2. Affected
individuals shared a chromosome 16 haplotype flanked by
D16S3103 and D16S489, spanning 37.9 Mb, with a
smaller suggestive disease haplotype spanning 24.4 Mb
defined by recombination in an elderly unaffected indi-
vidual. Importantly, this smaller region does not overlap
with FUS. Whole-exome sequencing identified four vari-
ants present in the maximal critical region that segregate
with disease. Linkage analysis incorporating these variants
generated a maximum multipoint LOD score of 3.0. These
results support the identification of a locus on chromosome
16p12.1–16q12.2 responsible for an unusual cluster of
neurodegenerative phenotypes. This region overlaps with a
separate locus on 16q12.1–q12.2 reported in an indepen-
dent ALS family, indicating that this region may harbour a
second major locus for FTD-ALS.
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Introduction
Frontotemporal dementia (FTD) is a clinically and patho-
logically heterogeneous group of disorders that can present
with personality and behavioural changes or language
deficits [33]. The discovery of MAPT mutations in families
with hereditary dementia with parkinsonism [16] allowed
the unified classification of a group of families with a wide
spectrum of clinical and pathological diagnoses. Dementia
in these families was often atypical but most resembled
FTD [27], with changes in personality, behaviour and
insight, together with extrapyramidal motor features.
Similarly, a group of MAPT-negative families with heter-
ogeneous clinical features was later shown to have
mutations in the granulin gene (GRN) [6]. Some families
with GRN mutations have a diagnosis of corticobasal
syndrome (CBS) [7, 30].
Amyotrophic lateral sclerosis (ALS) is characterised by
degeneration of upper and lower motor neurons, leading to
progressive muscle wasting, spasticity and ultimately
paralysis and death. Families with hereditary dementia and
ALS have been linked to a C9ORF72 hexanucleotide
repeat expansion [9, 31]. These families usually include
some affected members with pure ALS, while the majority
of affected members develop a dementia syndrome that is
often atypical or difficult to diagnose, but in most cases
eventually resembles FTD. Affected members with
dementia may also develop ALS during the course of their
disease. As well as MAPT, GRN and C9ORF72, other
genes have been found to harbour mutations in families
with FTD (e.g., VCP, CHMP2B) or ALS (e.g., SOD1,
TARDBP, FUS) [3, 35].
Several types of neuropathology are found in patients
with FTD, classified under the general rubric of fronto-
temporal lobar degeneration (FTLD). Most cases contain
filamentous inclusions made of one of three constitutive
neuronal proteins: tau (FTLD-tau), TAR DNA-binding
protein (FTLD-TDP) or fused in sarcoma (FTLD-FUS)
[22]. Cases with FTD-ALS most commonly have type B
FTLD-TDP pathology characterised by motor neuron-like
neuronal cytoplasmic inclusions (NCIs) [32]. In contrast,
corticobasal degeneration (CBD) has a distinctive FTLD-
tau pathology with ballooned neurons and tau-immunore-
active astrocytic plaques and threads [10]. In this study, we
describe a large multigenerational family (Aus-12) with a
clinical spectrum of FTD and ALS, and neuropathology
consistent with CBD FTLD-tau and type B FTLD-TDP.
Combined genome-wide linkage and whole-exome




The proband (IV:23) was referred to a memory clinic at age
56 with symptoms suggesting cognitive decline in the
context of a family history of young-onset dementia. She
subsequently visited a clinical genetics service, where a
detailed family history was compiled including available
medical records. Twelve individuals with dementia and
two with ALS were identified over four generations in a
pattern consistent with autosomal dominant inheritance.
Approval to approach relatives for a family genetics study
was granted by the Ethics Committee of the Women’s and
Children’s Hospital, Adelaide, and genetic studies were
approved by the Ethics Committee of Concord Hospital in
Sydney. The next of kin of individuals IV:5 and IV:7
consented to an autopsy study for brain research at the time
of death and tissue sections and neuropathological reports
for this study were obtained from the South Australian
Brain Bank. To determine final diagnoses for IV:5 and
IV:7, a retrospective review of their neuropathology was
performed using current diagnostic criteria for Alzheimer’s
disease, dementia with Lewy bodies, FTLD, ALS, and
other neurodegenerative syndromes including CBD, pro-
gressive supranuclear palsy, and vascular dementia [8, 10,
15, 17, 22, 24, 26]. Brain tissue from a previously pub-
lished familial FTLD-TDP case with a R493X GRN
mutation [29] and two neuropathologically confirmed CBD
FTLD-tau cases, obtained from the Sydney Brain Bank,
were examined for comparison.
Immunohistochemical analysis
Immunohistochemistry was performed on formalin-fixed
paraffin-embedded 7–10-lm superior frontal cortex, hip-
pocampus or spinal cord sections. We performed standard
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peroxidase immunohistochemistry with citrate buffer anti-
gen retrieval and 0.5 % cresyl violet counterstaining [19].
Antibodies used were for ubiquitin (Z0458, DAKO, Den-
mark, diluted 1:200), phosphorylated tau (MN1020,
PIERCE, USA, diluted 1:10,000), phosphorylated TDP
(BC001487, PTG, USA, diluted 1:500), FUS (HPA008784,
Sigma, Australia, diluted 1:1,000), a-internexin (32-3600,
ZYMED Laboratories, USA, diluted 1:50) and phosphor-
ylated 200 kD neurofilament (MAS330, Seralab, UK,
diluted 1:200). Reaction specificity was confirmed by
omitting primary antibodies. Double immunofluorescent
labelling was performed to detect phosphorylated tau and
phosphorylated TDP. After antigen retrieval, sections were
treated for autofluorescence by immersion in 0.25 %
potassium permanganate solution for 7 min, rinsed with
water and placed in 1 % potassium metabisulphite, 1 %
oxalic acid until the sections returned to their original
colour. Tau and TDP immunoreactivity was visualised with
Alexa Fluor 568 goat anti-rabbit and Alexa Fluor 488 goat
anti-mouse secondary antibodies (Invitrogen) on a confocal
microscope (C190; Nikon Corporation, Tokyo, Japan). A
section without primary antibodies was included for each
staining procedure as a negative control. In addition, a
mixture of the secondary antibodies was applied to sections
with only one primary antibody incubated on each section.
FTLD-TDP was classified into one of four subtypes [21]
based on the morphology and laminar distribution of TDP-
immunopositive inclusions in the affected brain regions.
Genetic evaluation of family
Blood was collected from 13 family members and DNA
extracted. DNA was screened for mutations in known
dementia/ALS genes (Supplementary Table 1). A 10-cM
genome-wide scan was performed on DNA from 12 indi-
viduals by the Australian Genome Research Facility (AGRF)
with microsatellite markers from the ABI-400 set (ABI Prism
Linkage Mapping Set, version 2.5, MD-10). Parametric pair-
wise and multipoint LOD scores were calculated and simu-
lation analyses were performed using MERLIN v1.1.2 [2].
Autosomal dominant inheritance of a single genetic locus for
all clinical variants was assumed with a phenocopy rate of
0.005, a disease gene frequency of 0.001 and equal marker
allele frequencies. Seven liability classes were established
based on pedigree data with 1 % penetrance—age \ 25
years, 8 %—between 26 and 34 years, 22 %—between 35
and 44 years, 46 %—between 45 and 54 years, 71 %—
between 55 and 64 years, 91 %—between 65 and 74 years,
and 95 %—age [ 75 years. Individuals were assigned a
liability class based on age of onset for affected cases and age
at last consultation for asymptomatic cases.
High-resolution fine mapping of chromosome 16 was
performed at the AGRF using microsatellite markers
selected from the UCSC Human Genome Browser Gate-
way (http://genome.ucsc.edu/cgi-bin/hgGateway). Primers
were fluorescently labelled with 6-FAM and PCR was
carried out according to standard protocols. For fine map-
ping, allele frequencies were derived from a cohort of
European ancestry Australian normals [13], from CEPH
family data (http://www.cephb.fr/en/cephdb/), or were
assumed to be equal if information was unavailable. The
novel markers 16GT and 21AC were amplified in-house
and amplified products were run on the Applied Biosys-
tems 3730 DNA Analyser at the Ramaciotti Centre,
University of New South Wales. We generated allele fre-
quencies for these markers from a panel of 24 unrelated
European ancestry healthy controls.
Whole-exome sequencing was performed on one unaf-
fected and four affected Aus-12 family members, using
100-bp paired-end sequencing on the Illumina HiSeq2000
with 409 coverage, by Macrogen (Seoul, Korea).
Results
Clinical description of the Aus-12 family
Family members of pedigree Aus-12 (Fig. 1) were the
subjects of detailed clinical review (Table 1). The proband
(IV:23) presented with memory impairments and was given
a final clinical diagnosis of FTD. The proband’s mother,
III:17, died at 61 with dementia; four of her nine siblings
were affected with dementia and died before age 65. The
proband’s grandmother and great-grandmother were
affected with dementia, dying at 64 and 40, respectively.
Four first cousins of the proband had presenile dementia;
two died with ALS aged 45 and 49 years, respectively; and
one was diagnosed with FTD-ALS. Detailed clinical notes
for pedigree members IV:23, IV:5, IV:7 and IV:12 are
available in Supplementary Material.
Neuropathological analysis of Aus-12
Case IV:5 The brain weighed 1,003 g. Microscopy confirmed
severe fronto-temporal atrophy with diffuse neuronal loss and
reactive gliosis maximal in the temporal poles where status
spongiosis was present (Supplementary Table 2). The main
immunocytochemical pathology was that of a tauopathy
with the phospho-tau (AT8) immunostains showing promi-
nent cytoplasmic neuronal reactivity (‘‘pre-tangles’’) and
occasional neurofibrillary tangles involving subsets of hip-
pocampal CA1 pyramidal neurons, temporal neocortex,
frontal and parietal cortex in association with numerous AT8
immunoreactive neuronal threads (Fig. 2a–c). There was
limited overall loss of hippocampal CA1 neurons (Fig. 2e).
Many of the dentate granule cells showed phospho-tau
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cytoplasmic immunoreactivity (Fig. 2c). Occasional phos-
phorylated neurofilament and tau immunopositive ‘ballooned
neurons’ were noted in the frontal and hippocampal sections
but this was a rare finding. Phospho-tau immunoreactive
astrocytic plaques (Fig. 2d) and coiled fibres were also pres-
ent. A prominent subset of neurons in the nucleus basalis of
Meynert showed AT8 immunoreactive cytoplasmic staining
in association with numerous positive neuronal threads.
Fig. 1 Haplotype analysis of the chromosome 16p12.3–16q12.2
region in family Aus-12. Black symbols show individuals with
dementia, either AD or FTD; grey symbols individuals with ALS. A
diagonal line marks deceased subjects. Individuals with DNA
available are asterisked. Inferred haplotypes are in parentheses.
Allele data for 12 markers in this region are shown. Some haplotypes
were presented for review but have been omitted from publication, to
protect confidentiality of at-risk individuals
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Subsets of neurons and astrocytes in the caudate nucleus
showed positive AT8 cytoplasmic immunostaining, whereas
in the putamen and globus pallidus astrocyte immunoreac-
tivity was more prominent than neuronal staining. Phospho-
TDP-43 immunoreactive NCIs were found in both superficial
and deep cortical laminae of the frontal (Fig. 2f, inset) and
temporal cortex. A subset of the dentate granule cells showed
phospho-TDP-43 immunopositive NCIs (Fig. 2f). Double
labelling immunofluorescence revealed that cytoplasmic
phospho-tau immunoreactivity and phospho-TDP-43 immu-
nopositive NCIs were found together in approximately 20 %
of hippocampal dentate granule cells and 5 % of cortical
neurons (Supplementary Fig. 1c, f, j, k). While many neurons
and glia contained AT8 immunoreactivity (Supplementary
Fig. 1a, d, g), a minority of phospho-TDP-43 immunopositive
NCIs were found in neurons that were not immunoreactive for
phospho-tau (Supplementary Fig. 1c, k). No FUS or a-in-
ternexin immunoreactive inclusion pathology was observed.
In the midbrain there was neuronal loss, depigmentation and
gliosis of the substantia nigra. A subset of surviving substantia
nigra neurons showed cytoplasmic AT8 immunoreactivity, as
did scattered periaqueductal neurons in association with
immunoreactive neurites. The AT8 immunostains also
showed intracytoplasmic staining in neurons of the locus
coeruleus, scattered neurons of midline raphe nuclei, dorsal
motor vagal nuclei, nuclei ambiguii and reticular formation in
association with immunoreactive neurites. The findings are
those of CBD FTLD-tau associated with type B FTLD-TDP
without significant bulbar motor neuron involvement.
Case IV:7 The brain weighed 1,160 g. There was more
severe frontotemporal atrophy in this case, and the substantia
nigra was severely depigmented. Microscopy showed a
similar pattern and type of neuropathological features to
those described above but with greater neuronal loss
(Supplementary Table 2), consistent with more advanced
CBD FTLD-tau and type B FTLD-TDP. Western blot anal-
ysis of the sarkosyl-insoluble fraction of frontal pole tissue
revealed that the insoluble tau species present in this case was
consistent with a 4-repeat tauopathy, as seen with other CBD
cases [5, 34] (Supplementary Fig. 2). The spinal cord was
also available in this case and segmental sections showed
preservation of the corticospinal tracts (myelin stain). There
was patchy loss of anterior horn cells in the cervical and
thoracic spinal cord segments and ubiquitinated, neurofila-
ment-immunoreactive motor neurons, neurites (Fig. 2g, h)
and NCI (Fig. 2g, inset) were observed in these sections,
along with rare phospho-tau immunoreactivity (Fig. 2i).
Phospho-TDP immunoreactivity was restricted to neurites
and granular staining in small neurons (Fig. 2j) and absent in
anterior horn cells. No FUS or a-internexin immunoreac-
tivity was observed in these spinal cord sections.
The phospho-tau neuropathology of Aus-12 cases clo-
sely resembled that in the CBD FTLD-tau cases examined.
The TDP-43 neuropathology was similar in amount and
distribution but not structural type to that observed in the
GRN mutation-positive FTLD-TDP case. Greater deposi-
tion in the dentate gyrus and fewer phospho-TDP-positive
neurites was observed in the Aus-12 cases (Supplementary
Material). The motor neuron involvement was mild com-
pared with classic end-stage ALS cases and was without
TDP or FUS deposition, although ubiquitinated inclusions
were present (as has been observed in other familial ALS
cases negative for known mutations) [23].
Genetic analysis of Aus-12
DNA from IV:5, IV:6 and IV:24 was subjected to DNA
sequence analysis of the coding regions and flanking
Table 1 Clinical summary of
family Aus-12
Subject Age at onset (years) Age at death (years) Diagnosis/clinical features
I:2 30 40 Died after 10 years in psychiatric hospital
II:2 56 64 ‘Presenile Alzheimer’s disease’
III:1 53 59 ‘Inherited dementia’
III:7 49 56 Unspecified presenile dementia
III:9 ? 64 Unspecified presenile dementia
III:12 ? 62 Memory loss, apathy, lacked insight
III:17 51 61 Memory loss, wandering, behavioural problems
IV:4 56 68 Memory loss, behavioural problems
IV:5 54 64 ‘FTD with aphasia’
IV:6 58 67 Unspecified presenile dementia
IV:7 62 69 FTD-ALS, Paget’s disease, parkinsonism
IV:9 ? 45 Probable ALS
IV:12 ? 49 ALS
IV:23 56 68 FTD
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intronic sequences for known dementia and ALS genes
(Supplementary Table 1). No mutations were detected.
We undertook a genome-wide linkage analysis on 12
pedigree members, five of whom were classed as affected.
Six regions generated two-point LOD scores C1, on
chromosomes 3 (D3S1285, LOD = 1.3), 12 (D12S352,
1.0), 15 (D15S117, 1.5; D15S127, 1.1), 16 (D16S415, 1.2)
and 20 (D20S107, 1.4); however, with multipoint analy-
sis the only regions with a LOD score C1 were on
chromosome 16 (D16S415, LOD = 2.7; D16S516, 1.1).
Examination of haplotypes revealed that affected individ-
ual IV-23 was identical by state rather than by descent at
D16S516: this individual harboured the same haplotype as
unaffected sibling IV-24 at D16S516 and flanking markers
D16S515 and D16S3091 (data not shown). In contrast,
alleles at D16S415 and upstream markers D16S3046,
D16S3068 and D16S3136 were shared by all affected
individuals. This region on chromosome 16 was therefore
fine mapped with 21 additional markers. Supplementary
Table 3 details two-point LOD scores, showing a maxi-
mum of 2.4 (h = 0) at D16S3396. Gene-dropping
simulation analyses indicated that two chromosome 16
microsatellite markers exceeded the genome-wide 1 %
significance threshold for 100 simulations. Multipoint
analysis with MERLIN yielded a maximum LOD score of
2.9 for all markers from D16S753 to D16S2623 inclusive
and excluded linkage (LOD \ -2) at other FTD loci
(CHMP2B, C9ORF72, VCP, GRN/MAPT) (Supplementary
Fig. 3).
Haplotypes were constructed for the 16p12.1–q12.2
region in Aus-12 (Fig. 1). Recombinations in this family
defined a 37.9-Mb region flanked by the markers
D16S3103 and D16S489, in which a common haplotype
was shared by all affected individuals (Fig. 3b). A smaller
suggestive disease haplotype spanning 24.4 Mb was
defined by recombination at D16S753 in elderly unaffected
individual III:15. This region overlaps with a separate locus
on 16q12.1–q12.2 reported in an ALS family by Abalkhail
et al. [1] (Fig. 3b).
We performed whole-exome sequencing of affected
individuals IV:5, IV:6, IV:17, IV:23 and elderly unaffected
individual III:15. No pathogenic variants were identified in
known dementia or ALS genes, including FUS on chro-
mosome 16 (Supplementary Table 1). We identified seven
variants from the exome sequencing data within the Aus-12
maximal critical region that were absent from dbSNP131,
and were detected in at least 2 affected individuals and
resequenced them in all 13 Aus-12 DNA samples. Four
variants were present in all affected individuals and absent
in the elderly unaffected individual, two of which were also
absent from public databases of normal human variation
(Table 2). One of these variants, g.48576222C[A, was
detected in 2/934 healthy Australian individuals of Euro-
pean ancestry by examination of exome sequencing data
(Dr Paul Leo and Prof Matthew Brown, personal commu-
nication). The second variant, g.50825515A[G, leads to
the substitution of methionine to valine at amino acid
position 719 of the cylindromatosis protein, CYLD. This
variant is present within the region of overlap with the
chromosome 16q12.1—linked ALS pedigree [1] (Table 2).
We used nine rare variants detected by whole-exome
sequencing and confirmed by Sanger sequencing to repeat
the linkage analysis. This generated a maximum two-point
LOD score of 2.7 for markers g.31484758G[A,
g.48576222C[A, g.50825515A[G and g.53721944A[G
(Supplementary Table 3) and a maximum multipoint LOD
score of 3.0 for markers 16GT through to g.53721944A[G
inclusive (Fig. 3a).
Discussion
In this study, we describe a complex FTD-ALS family with
co-existing CBD and TDP neuropathology. The clinical
presentations in this family are heterogeneous. The
majority of the affected individuals presented initially with
AD-like symptoms and/or motor disorders, rather than the
typical presentation of FTD. For example, the proband
(IV:23) presented with AD-like symptoms, but soon after
developed significant personality and behavioural change,
with disinhibition, socially inappropriate and obsessional
behaviour, and a lack of insight and was diagnosed with
FTD. Early memory impairment suggestive of AD is also
observed amongst GRN mutation carriers [18, 30], some-
times in association with motor disorders. Patient IV:7,
who was initially diagnosed with Paget’s disease, later
developed clinical symptoms consistent with parkinsonism
and ALS. ALS was also present as a pure syndrome in two
other family members. In MAPT mutation carriers, ALS
tends to be a late manifestation in patients already afflicted
Fig. 2 Phospho-tau and phospho-TDP neuropathology in case IV:5
(a–f), case IV:7 (g–j) and an independent CBD FTLD-tau case (k–m).
Numerous phospho-tau-immunopositive threads in the frontal cortex
(a) and white matter (b). c Dentate granule cells showing extensive
phospho-tau immunoreactivity. d Phospho-tau-immunoreactive astro-
cytic plaque in frontal cortex. e Nissl staining showing limited loss of
CA1 hippocampal pyramidal neurons. Phospho-TDP-immunopositive
NCIs (arrows) in the dentate gyrus (f) and frontal cortex (f, inset).
Ubiquitin- (g) and phosphorylated 200kD neurofilament- (h) immu-
nopositive motor neurons, NCI and neurites in the cervical spinal
cord. Rare phospho-tau immunoreactivity was observed in neurites,
glia and small spinal cord neurons (i) and some phospho-TDP-
immunopositive granules were observed in spinal motor neurons in
the absence of TDP-positive inclusions (j). In the case of sporadic
CBD (k–m), phospho-tau-immunoreactive astrocytic plaques, neu-
rons and threads were seen in the frontal cortex (k), phospho-tau-
immunoreactive glia and threads in the white matter (l), and diffuse
cytoplasmic phospho-tau immunoreactivity was observed in the
dentate granule cells (m)
b
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with parkinsonism, rather than a separate entity [20, 37].
Thus, clinical heterogeneity is not uncommon and has been
described in other families with GRN and MAPT mutations.
The Aus-12 pedigree represents the first to our knowledge
in which affected individuals have neuropathologically
confirmed CBD FTLD-tau as well as type B FTLD-TDP.
Concomitant phospho-tau and phospho-TDP neuropathol-
ogy is not rare and has now been reported in many different
sporadic neurodegenerative disorders, but particularly in
AD and CBD [36]. Interestingly, although ALS is usually
characterised by TDP-43 pathology [4, 28], studies have
demonstrated significant deposition of phospho-tau in
brains of ALS patients with cognitive impairment [14,
38]. Our western blot analyses (Supplementary Fig. 2)
clearly show that the insoluble tau species comprise solely
four repeat isoforms. This finding corresponds to a path-
ological diagnosis of CBD or PSP, rather than Pick’s
disease [11]. To further differentiate between these two
highly related disorders would require the presence of
balloon neurons (Fig. 2) and astrocytic plaques for CBD,
or globose tangles and tufted astrocytes for PSP, or per-
haps the identification of a low molecular weight tau
species that co-migrates with CBD and not PSP protein
species [11]. The underlying phospho-TDP neuropathol-
ogy of IV:5 and IV:7 was consistent with type B TDP-43
neuropathology, a pathology described in most familial
FTD-ALS cases arising from C9ORF72 mutation [12, 25].
However, the spinal cord TDP pathology was more lim-
ited, characterised by the occasional staining of neurites,
with the ubiquitinated motor neuron inclusions not
immunoreactive for TDP or tau. Co-immunofluorescence
analysis revealed considerable overlap between the brain
regions affected by the phospho-tau and phospho-TDP
pathology, although both pathologies occurred indepen-
dently, and more phospho-tau was observed in these
cases. While the neuropathological depositions appear
a
b
Fig. 3 Linkage analysis of Aus-12. a Multipoint linkage analysis of
chromosome 16, generated using MERLIN program. Positions of
markers flanking critical recombinations in Aus-12 family members are
indicated. b Haplotype analysis of chromosome 16p13.11–16q22.2.
Top Physical positions of microsatellite markers and single-nucleotide
variants used for haplotype analysis. Middle Haplotypes of affected
individuals IV:23 and IV:5 and elderly unaffected individual III:15.
The disease haplotype is indicated in black. The maximal critical
region defined in this study and the critical region detected in the ALS
family reported in Abalkhail et al. [1] are depicted below. Bottom
RefSeq genes present in the minimal critical region, defined by
overlap of Aus-12 and Abalkhail et al. critical regions
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unique in family Aus-12, the relationship between the
pathologies observed remains unclear.
Genome-wide linkage analysis resulted in the identifi-
cation of a disease locus on chromosome 16p12.1–q12.2.
The region overlaps with a known ALS/FTD gene, FUS
(OMIM *137070). However, we did not detect any FUS
mutations in Aus-12, using both Sanger sequencing and
whole-exome sequencing. Individuals IV:17 and IV:23 are
heterozygous for SNP rs741810 in FUS exon 3 and IV:5 and
IV:6 are heterozygous for rs1052352 in exon 4, indicating
that both alleles are present at this locus. In addition, the
smaller suggestive region defined by recombination in
individual III:15 does not include the FUS locus. Intrigu-
ingly, the Aus-12 disease region overlaps with that
identified in an independent ALS family (Fig. 3b), with
maximal multipoint LOD scores of 2.06 at D16S3080 and
D16S411 [1]. This ALS family is negative for FUS muta-
tions and the hexanucleotide repeat expansion in C9ORF72
(Prof Jacqueline de Belleroche, personal communication).
Assuming that the disease in this family is due to the same
genetic cause, the recombination breakpoint observed in
this study at D16S489 slightly narrows the telomeric
boundary of the combined published minimal disease
region by 26 kb. This combined critical region contains 27
RefSeq genes (Fig. 3b). We detected one nonsynonymous
variant within these genes by whole-exome sequencing:
Met719Val in CYLD. CYLD was previously sequenced in
affected individuals from the Abalkhail et al. [1] ALS
pedigree but no mutations were identified (Prof Jacqueline
de Belleroche, personal communication). CYLD Met-719 is
invariant in mammals, chicken, frog and zebrafish, but is
valine in Drosophila CYLD homologues (data not shown).
In silico analysis using programs Align GVGD (http://
agvgd.iarc.fr/agvgd_input.php/), PolyPhen-2 (http://gene
tics.bwh.harvard.edu/pph2/) and SIFT (http://sift.jcvi.
org/) predicted that this substitution was not likely to be
pathogenic. This implies that the disease variant is either
located in non-exonic sequence or is of a type that cannot be
detected by direct sequencing, such as a genomic rear-
rangement, copy-number variant, or a repeat expansion.
The identification of two independent families with
linkage to the same locus indicates that this region may
harbour a second major FTD-ALS gene. The positional
cloning of the major FTD causative loci have been
instrumental in the elucidation of pathogenic mechanisms
underlying the various neuropathological variants, includ-
ing MAPT and GRN [6, 16]. Genetic evaluation of family
Aus-12 will further aid our understanding of disease
pathogenesis in FTD-ALS cases with both phospho-tau and
phospho-TDP deposition.
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Table 2 Variants detected by whole-exome sequencing
gDNA changea Gene Variant type Segregates with disease?b MAF 1000Gc MA count EVSd MAF used for
linkage analysis
g.31151860G[A PRSS36 Missense (p.P707L) No (RNC) 18/8,548 0.002
g.31447539G[A ZNF843 Missense (p.P211L) No 0 0/3,182 0.001
g.31484758G[A TGFB1I1 Intronic (c.IVS1-4G[A) Yes 0.0118 109/8600 0.012
g.48576222C[A N4BP1 30UTR (c.2691*593C[A) Yes 0 (RNC) 0.001
g.50825515A>G CYLD Missense (p.M719V) Yes 0 0/8,138 0.001
g.53653005G>C RPGRIP1L Missense (p.A1183G) No 0.0176 132/8,600 0.016
g.53721944A>G RPGRIP1L Intronic (c.IVS4-67A>G) Yes 0.0059 (RNC) 0.0059
g.71488166T[Ce ZNF23 Intronic (c.IVS3-45T[C) No 0.0059 (RNC) 0.0059
MA minor allele, MAF minor allele frequency, RNC region not covered
a Variants present in region of overlap with a chromosome 16q12.1—linked ALS pedigree [1] are in bold. Variant nomenclature is according to
the recommendations of the Human Genome Variation Society (http://www.hgvs.org/mutnomen/). Genomic co-ordinates on chromosome 16
refer to the human reference sequence GRCh37/hg19
b Presence in all affected individuals and absence in elderly unaffected individuals
c Frequency in CEU population of the 1,000 Genomes dataset (http://www.ncbi.nlm.nih.gov/variation/tools/1000genomes/)
d Count in European American population of the Exome Variant Server (http://evs.gs.washington.edu/EVS/)
e Variant lies outside Aus-12 maximal critical region
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